Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 62, 2002 - Issue 3
Submit an article Journal homepage
58
Views
27
CrossRef citations to date
0
Altmetric
Research Article

Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up

M. K. Tuxen Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark;
,
G. SöLétormos Department of Clinical Biochemistry, Hillerod Hospital, Hillerod, Denmark
&
P. Dombernowsky Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark;
Pages 177-188 | Published online: 08 Jul 2009

  • Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-7.
  • Tuxen MK. Tumor marker CA 125 in ovarian cancer. J Tumor Marker Oncol 2001; 16: 49-68.
  • Sölétormos G, Nielsen D, Schioler V, Skovsgaard T, Winkel P, Mouridsen HT, Dombemowsky P. A novel method for monitoring high-risk breast cancer with tumor markers: CA IS.3 compared to CEA and TPA. Ann Oncol 1993; 4: 861-9.
  • Sölétormos G, Nielsen D, Schioler V, Skovsgaard T, Dombemowsky P. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 1996; 42: 564-75.
  • Bidart JM, Thuillier F, Augereau Ch, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H. Kinetics of serum tumour marker concentrations and usefulness in clinical monitoring. Clin Chem 1999; 45: 1695-707.
  • Tuxen MK, Sölétormos G, Dombemowsky P. Serum tumor marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001; 84: 1301-7.
  • Boscato LM, Stuart MC. Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988; 34: 27-33.
  • Nicholson S, Fox M, Epenetos A, Rustin G. Immunoglobulin Inhibiting Reagent® : evaluation of a new method for eliminating spurious elevations in CA 125 caused by HAMA. Int J Biol Markers 1996; 11:46-9.
  • Bast RC, Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Jr., Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med 1983; 309: 883-7.
  • Tuxen MK, Sölétormos G, Rustin GJS, Nelstrop AE, Dombemowsky P. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer. Scand J Clin Lab Invest 2000; 60: 713-22.
  • Fraser CG, Hyltoft Petersen P. The importance of imprecision. Ann Clin Biochem 1991; 28: 207-11.
  • Fraser CG, Hyltoft Petersen P, Larsen ML. Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem 1990; 36: 1625-8.
  • Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford: Blackwell Scientific Publications; 1994.
  • Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study. Ann Oncol 1996; 7: 361-4.
  • Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
  • Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55.
  • Rustin G, Tuxen M. Use of CA 125 in follow-up of ovarian cancer. Lancet 1996; 348: 191-2.
  • Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhaver EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Trope C, Tuxen MK, Vergote I, Vermerken JB, Willemse PH. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10: S87-92.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.